These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 21667322)

  • 1. Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission.
    Mark M; Thürlimann B
    Med Oncol; 2012 Sep; 29(3):1477-8. PubMed ID: 21667322
    [No Abstract]   [Full Text] [Related]  

  • 2. Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer.
    Inaba K; Arimoto T; Hoya M; Kawana K; Nakagawa S; Kozuma S; Taketani Y
    Med Oncol; 2012 Jun; 29(2):1255-7. PubMed ID: 21390517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin.
    Meng L; Huang L; Xu Y; Zhang W
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):3-7. PubMed ID: 31377831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary.
    Markman M
    Expert Opin Pharmacother; 2006 Aug; 7(11):1469-74. PubMed ID: 16859430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer.
    Huober J; Schoch O; Templeton A; Spirig C; Thürlimann B
    Chemotherapy; 2010; 56(1):69-70. PubMed ID: 20145394
    [No Abstract]   [Full Text] [Related]  

  • 6. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
    Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
    Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer.
    Torrisi R; Montagna E; Scarano E; Dellapasqua S; Cancello G; Iorfida M; Luini A; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2011 Feb; 20(1):34-8. PubMed ID: 20638282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer.
    Rom J; Bechstein S; Domschke C; Golatta M; Mayer C; Heil J; Thum J; Smetanay K; Windemuth-Kieselbach C; Wallwiener M; Marme F; Schuetz F; Sohn C; Schneeweiss A
    Anticancer Drugs; 2014 Feb; 25(2):219-24. PubMed ID: 24247203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.
    Mlineritsch B; Schabel-Moser R; Andel J; Fridrik M; Moik M; Mayer P; Russ G; Rass C; Greil R;
    Onkologie; 2009 Feb; 32(1-2):18-24. PubMed ID: 19209014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intertrigo-like eruption caused by pegylated liposomal doxorubicin (PLD).
    Sánchez Henarejos P; Ros Martínez S; Marín Zafra GR; Alonso Romero JL; Navarrete Montoya A
    Clin Transl Oncol; 2009 Jul; 11(7):486-7. PubMed ID: 19574209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Treatment of a Locally Recurrent and Metastatic Malignant Phyllodes Tumor with Accelerated Radiotherapy and Nab-Paclitaxel, Cisplatin, and Liposomal Doxorubicin Chemotherapy.
    Koukourakis IM; Zygogianni A; Kouloulias V; Koukourakis MI
    Chemotherapy; 2021; 66(3):82-86. PubMed ID: 34233328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of new-onset heart failure and overall survival in metastatic breast cancer patients treated with liposomal doxorubicin.
    Szmit S; Grela-Wojewoda A; Talerczyk M; Kufel-Grabowska J; Streb J; Smok-Kalwat J; Iżycki D; Chmielowska E; Wilk M; Sosnowska-Pasiarska B
    Sci Rep; 2020 Oct; 10(1):18481. PubMed ID: 33116159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Liposomal doxorubicin in patients with breast cancer and concomitant cardiovascular diseases - interdisciplinary expert opinion].
    Szmit S; Filipiak KJ; Litwiniuk M; Opolski G; Wysocki P; Zaborska B; Krzakowski M
    Kardiol Pol; 2016; 74(9):1031-6. PubMed ID: 27654476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is the right way to administer pegylated liposomal doxorubicin in breast cancer therapy?
    Grenader T; Gabizon A
    J Clin Oncol; 2010 Apr; 28(12):e193-4; author reply e195-6. PubMed ID: 20194839
    [No Abstract]   [Full Text] [Related]  

  • 15. Striking follicular eruption to pegylated liposomal doxorubicin.
    Dai J; Micheletti R; Rosenbach M; Chu EY
    Am J Dermatopathol; 2014 Jul; 36(7):590-1. PubMed ID: 24614205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of recurrent breast cancer with carcinomatous pleurisy successfully treated with combined chemoendocrine-therapy of CTF (CPA, THP and 5-FU) and anastrozole following instillation therapy 12 years after radical mastectomy].
    Mori K; Chiba N; Yamamoto Y; Yonekawa H
    Gan To Kagaku Ryoho; 2002 Dec; 29(13):2565-8. PubMed ID: 12506484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal toxicity with liposomal doxorubicin in metastatic breast cancer.
    Yemm KE; Alwan LM; Malik AB; Salazar LG
    J Oncol Pharm Pract; 2019 Oct; 25(7):1738-1742. PubMed ID: 30170515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interstitial lung disease associated with docetaxel in a patient treated for breast cancer - a case report.
    Pankowska-Supryn M; Załęska M; Roszkowska-Śliż B; Roszkowski-Śliż K
    Pneumonol Alergol Pol; 2015; 83(5):378-82. PubMed ID: 26378999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recall inflammatory skin reaction after use of pegylated liposomal doxorubicin in site of previous drug extravasation.
    Saini A; Berruti A; Sperone P; Bitossi R; Tampellini M; Dogliotti L; Gorzegno G
    Lancet Oncol; 2006 Feb; 7(2):186-7. PubMed ID: 16455484
    [No Abstract]   [Full Text] [Related]  

  • 20. The Safety of Pegylated Liposomal Doxorubicin Plus Irinotecan in Recurrent Ovarian Cancer Patients: A Phase I Trial.
    Miyahara D; Ueda T; Katsuda T; Maehara M; Fukagawa S; Miyata K; Nam SO; Kondo H; Miyamoto S
    Anticancer Res; 2015 Aug; 35(8):4521-5. PubMed ID: 26168496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.